Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Dal, J, Leisner, MZ, Hermansen, K, Farkas, DK, Bengtsen, M, Kistorp, C, Nielsen, EH, Andersen, M, Feldt-Rasmussen, U, Dekkers, OM, Sørensen, HT & Jørgensen, JOL 2018, 'Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature' The Journal of clinical endocrinology and metabolism, bind 103, nr. 6, s. 2182-2188. https://doi.org/10.1210/jc.2017-02457

APA

CBE

Dal J, Leisner MZ, Hermansen K, Farkas DK, Bengtsen M, Kistorp C, Nielsen EH, Andersen M, Feldt-Rasmussen U, Dekkers OM, Sørensen HT, Jørgensen JOL. 2018. Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature. The Journal of clinical endocrinology and metabolism. 103(6):2182-2188. https://doi.org/10.1210/jc.2017-02457

MLA

Vancouver

Author

Dal, Jakob ; Leisner, Michelle Z ; Hermansen, Kasper ; Farkas, Dóra Körmendiné ; Bengtsen, Mads ; Kistorp, Caroline ; Nielsen, Eigil H ; Andersen, Marianne ; Feldt-Rasmussen, Ulla ; Dekkers, Olaf M ; Sørensen, Henrik Toft ; Jørgensen, Jens Otto Lunde. / Cancer Incidence in Patients With Acromegaly : A Cohort Study and Meta-Analysis of the Literature. I: The Journal of clinical endocrinology and metabolism. 2018 ; Bind 103, Nr. 6. s. 2182-2188.

Bibtex

@article{49ed5067af2a4b74a7d14e0ccd45fe96,
title = "Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature",
abstract = "Context: Acromegaly has been associated with increased risk of cancer morbidity and mortality, but research findings remain conflicting and population-based data are scarce. We therefore examined whether patients with acromegaly are at higher risk of cancer.Design: A nationwide cohort study (1978 to 2010) including 529 acromegaly cases was performed. Incident cancer diagnoses and mortality were compared with national rates estimating standardized incidence ratios (SIRs). A meta-analysis of cancer SIRs from 23 studies (including the present one) was performed.Results: The cohort study identified 81 cases of cancer after exclusion of cases diagnosed within the first year [SIR 1.1; 95{\%} confidence interval (CI), 0.9 to 1.4]. SIRs were 1.4 (95{\%} CI, 0.7 to 2.6) for colorectal cancer, 1.1 (95{\%} CI, 0.5 to 2.1) for breast cancer, and 1.4 (95{\%} CI, 0.6 to 2.6) for prostate cancer. Whereas overall mortality was elevated in acromegaly (SIR 1.3; 95{\%} CI, 1.1 to 1.6), cancer-specific mortality was not. The meta-analysis yielded an SIR of overall cancer of 1.5 (95{\%} CI, 1.2 to 1.8). SIRs were elevated for colorectal cancer, 2.6 (95{\%} CI, 1.7 to 4.0); thyroid cancer, 9.2 (95{\%} CI, 4.2 to 19.9); breast cancer, 1.6 (1.1 to 2.3); gastric cancer, 2.0 (95{\%} CI, 1.4 to 2.9); and urinary tract cancer, 1.5 (95{\%} CI, 1.0 to 2.3). In general, cancer SIR was higher in single-center studies and in studies with <10 cancer cases.Conclusions: Cancer incidence rates were slightly elevated in patients with acromegaly in our study, and this finding was supported by the meta-analysis of 23 studies, although it also suggested the presence of selection bias in some earlier studies.",
author = "Jakob Dal and Leisner, {Michelle Z} and Kasper Hermansen and Farkas, {D{\'o}ra K{\"o}rmendin{\'e}} and Mads Bengtsen and Caroline Kistorp and Nielsen, {Eigil H} and Marianne Andersen and Ulla Feldt-Rasmussen and Dekkers, {Olaf M} and S{\o}rensen, {Henrik Toft} and J{\o}rgensen, {Jens Otto Lunde}",
year = "2018",
month = "6",
day = "1",
doi = "10.1210/jc.2017-02457",
language = "English",
volume = "103",
pages = "2182--2188",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The/Endocrine Society",
number = "6",

}

RIS

TY - JOUR

T1 - Cancer Incidence in Patients With Acromegaly

T2 - A Cohort Study and Meta-Analysis of the Literature

AU - Dal, Jakob

AU - Leisner, Michelle Z

AU - Hermansen, Kasper

AU - Farkas, Dóra Körmendiné

AU - Bengtsen, Mads

AU - Kistorp, Caroline

AU - Nielsen, Eigil H

AU - Andersen, Marianne

AU - Feldt-Rasmussen, Ulla

AU - Dekkers, Olaf M

AU - Sørensen, Henrik Toft

AU - Jørgensen, Jens Otto Lunde

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Context: Acromegaly has been associated with increased risk of cancer morbidity and mortality, but research findings remain conflicting and population-based data are scarce. We therefore examined whether patients with acromegaly are at higher risk of cancer.Design: A nationwide cohort study (1978 to 2010) including 529 acromegaly cases was performed. Incident cancer diagnoses and mortality were compared with national rates estimating standardized incidence ratios (SIRs). A meta-analysis of cancer SIRs from 23 studies (including the present one) was performed.Results: The cohort study identified 81 cases of cancer after exclusion of cases diagnosed within the first year [SIR 1.1; 95% confidence interval (CI), 0.9 to 1.4]. SIRs were 1.4 (95% CI, 0.7 to 2.6) for colorectal cancer, 1.1 (95% CI, 0.5 to 2.1) for breast cancer, and 1.4 (95% CI, 0.6 to 2.6) for prostate cancer. Whereas overall mortality was elevated in acromegaly (SIR 1.3; 95% CI, 1.1 to 1.6), cancer-specific mortality was not. The meta-analysis yielded an SIR of overall cancer of 1.5 (95% CI, 1.2 to 1.8). SIRs were elevated for colorectal cancer, 2.6 (95% CI, 1.7 to 4.0); thyroid cancer, 9.2 (95% CI, 4.2 to 19.9); breast cancer, 1.6 (1.1 to 2.3); gastric cancer, 2.0 (95% CI, 1.4 to 2.9); and urinary tract cancer, 1.5 (95% CI, 1.0 to 2.3). In general, cancer SIR was higher in single-center studies and in studies with <10 cancer cases.Conclusions: Cancer incidence rates were slightly elevated in patients with acromegaly in our study, and this finding was supported by the meta-analysis of 23 studies, although it also suggested the presence of selection bias in some earlier studies.

AB - Context: Acromegaly has been associated with increased risk of cancer morbidity and mortality, but research findings remain conflicting and population-based data are scarce. We therefore examined whether patients with acromegaly are at higher risk of cancer.Design: A nationwide cohort study (1978 to 2010) including 529 acromegaly cases was performed. Incident cancer diagnoses and mortality were compared with national rates estimating standardized incidence ratios (SIRs). A meta-analysis of cancer SIRs from 23 studies (including the present one) was performed.Results: The cohort study identified 81 cases of cancer after exclusion of cases diagnosed within the first year [SIR 1.1; 95% confidence interval (CI), 0.9 to 1.4]. SIRs were 1.4 (95% CI, 0.7 to 2.6) for colorectal cancer, 1.1 (95% CI, 0.5 to 2.1) for breast cancer, and 1.4 (95% CI, 0.6 to 2.6) for prostate cancer. Whereas overall mortality was elevated in acromegaly (SIR 1.3; 95% CI, 1.1 to 1.6), cancer-specific mortality was not. The meta-analysis yielded an SIR of overall cancer of 1.5 (95% CI, 1.2 to 1.8). SIRs were elevated for colorectal cancer, 2.6 (95% CI, 1.7 to 4.0); thyroid cancer, 9.2 (95% CI, 4.2 to 19.9); breast cancer, 1.6 (1.1 to 2.3); gastric cancer, 2.0 (95% CI, 1.4 to 2.9); and urinary tract cancer, 1.5 (95% CI, 1.0 to 2.3). In general, cancer SIR was higher in single-center studies and in studies with <10 cancer cases.Conclusions: Cancer incidence rates were slightly elevated in patients with acromegaly in our study, and this finding was supported by the meta-analysis of 23 studies, although it also suggested the presence of selection bias in some earlier studies.

U2 - 10.1210/jc.2017-02457

DO - 10.1210/jc.2017-02457

M3 - Journal article

VL - 103

SP - 2182

EP - 2188

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -

ID: 55074271